



EXPEDITED PROCEDURE
RESPONSE UNDER 37 C.F.R. § 1.116
GROUP ART UNIT: 1646

PATENT
Customer No. 22,852
Attorney Docket No. 3495.0187-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) **ATTN: BOX FINAL**
COEN et al.) Group Art Unit: 1646
Serial No.: 09/501,787) Examiner: M. Brannock, Ph.D.
Filed: February 11, 2000)
For: HYBRID TETANUS TOXOID)
PROTEINS THAT MIGRATE)
RETROGRADELY AND)
TRANSYNAPTICALLY INTO)
THE CNS)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

AMENDMENT AND RESPONSE
UNDER 37 C.F.R. § 1.116 TO PAPER NO. 13

In response to the Final Office Action dated June 18, 2002 (Paper No. 13), the period for reply having been extended by a petition for extension of time and fee payment filed concurrently herewith, and pursuant to 37 C.F.R. § 1.116, applicants submit the following remarks and propose that the application be amended as follows.

IN THE CLAIMS:

Please amend claim 31 as follows:

31. (Amended Two Times) A method for treating a central nervous system (CNS) disease comprising:

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

RECEIVED

DEC 20 2002

TECH CENTER 1600/2900

15/D
D. J.
1/13/03
NE

OK TO ENTER 1/29/03